Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

NCT06255262 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Cancer

Interventions

DRUG: Surufatinib
DRUG: Durvalumab

Sponsor

China Medical University, China